Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T Cells

Archivum Immunologiae et Therapiae Experimentalis

Volumn 58, Issue 3, 2010, Pages 165-178

  Davies, David Marc ^a   Maher, John ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Adoptive transfer; Cancer; Chimeric antigen receptor; Survival; T cell

Indexed keywords

CARBONATE DEHYDRATASE IX; CARCINOEMBRYONIC ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD30 ANTIGEN; CD44V6 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPITHELIAL CELL ADHESION MOLECULE; FOLATE RECEPTOR; GANGLIOSIDE GD2; GANGLIOSIDE GD3; IMMUNOGLOBULIN KAPPA CHAIN; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; MAJOR HISTOCOMPATIBILITY ANTIGEN; MUCIN 1; NERVE CELL ADHESION MOLECULE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE STEM CELL ANTIGEN; RITUXIMAB; T LYMPHOCYTE RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL EXPANSION; CELL SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HODGKIN DISEASE; HUMAN; IMMUNOGENICITY; KIDNEY CARCINOMA; LUNG CANCER; MELANOMA; NATURAL KILLER CELL; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SUICIDE GENE THERAPY; T CELL DEPLETION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TARGET CELL DESTRUCTION; THERAPY EFFECT;

ANIMALS; ANTIGENS, NEOPLASM; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; PROTEIN ENGINEERING; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 77953026179     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-010-0074-1     Document Type: Review

References (161)

1. Ahmed N, Ratnayake M, Savoldo B et al (2007) Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res 67:5957-5964.
2. Alarcon B, Swamy M, van Santen HM et al (2006) T-cell antigenreceptor stoichiometry: pre-clustering for sensitivity. EMBO Rep 7:490-495.
3. Altenschmidt U, Kahl R, Moritz D et al (1996) Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. Clin Cancer Res 2:1001-1008.
4. Altenschmidt U, Klundt E, Groner B (1997) Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression. J Immunol 159:5509-5515.
5. Alvarez-Vallina L, Hawkins RE (1996) Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric singlechain antibody variable fragment-CD28 receptors. Eur J Immunol 26:2304-2309.
6. Becker ML, Near R, Mudgett-Hunter M et al (1989) Expression of a hybrid immunoglobulin-T cell receptor protein in transgenic mice. Cell 58:911-921.
7. Bennour E, Ferrand C, Remy-Martin JP et al (2008) Abnormal expression of only the CD34 part of a transgenic CD34/herpes simplex virus-thymidine kinase fusion protein is associated with ganciclovir resistance. Hum Gene Ther 19:699-709.
8. Berger C, Flowers ME, Warren EH et al (2006) Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107:2294-2302.
9. Bonini C, Ferrari G, Verzeletti S et al (1997) HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versusleukemia. Science 276:1719-1724.
10. Brentjens RJ, Latouche JB, Santos E et al (2003) Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 9:279-286.
11. Brentjens RJ, Santos E, Nikhamin Y et al (2007) Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 13:5426-5435.
12. Brocker T, Karjalainen K (1995) Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med 181:1653-1659.
13. Burt RK, Drobyski WR, Seregina T et al (2003) Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions. Exp Hematol 31:903-910.
14. Carter P, Presta L, Gorman CM et al (1992) Humanization of an antip185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285-4289.
15. Chalmers D, Ferrand C, Apperley JF et al (2001) Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene. Mol Ther 4:146-148.
16. Charo J, Finkelstein SE, Grewal N et al (2005) Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Res 65:2001-2008.
17. Cheadle EJ, Gilham DE, Hawkins RE (2008) The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma. Br J Haematol 142:65-68.
18. Choudhuri K, Wiseman D, Brown MH et al (2005) T-cell receptor triggering is critically dependent on the dimensions of its peptide-MHC ligand. Nature 436:578-582.
19. Chung S, Wucherpfennig KW, Friedman SM et al (1994) Functional three-domain single-chain T-cell receptors. Proc Natl Acad Sci USA 91:12654-12658.
20. Cooper LJ, Topp MS, Serrano LM et al (2003) T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 101:1637-1644.
21. Cooper LJ, Al-Kadhimi Z, Serrano LM et al (2005) Enhanced antilymphoma efficacy of CD19-redirected influenza MP1- specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood 105:1622-1631.
22. Crumpacker CS (1996) Ganciclovir. N Engl J Med 335:721-729.
23. Darcy PK, Kershaw MH, Trapani JA et al (1998) Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma. Eur J Immunol 28:1663-1672.
24. Daudt L, Maccario R, Locatelli F et al (2008) Interleukin-15 favors the expansion of central memory CD8+ T cells in ex vivo generated, antileukemia human cytotoxic T lymphocyte lines. J Immunother 31:385-393.
25. Davis SJ, van der Merwe PA (2006) The kinetic-segregation model: TCR triggering and beyond. Nat Immunol 7:803-809.
26. DeBenedette MA, Shahinian A, Mak TW et al (1997) Costimulation of CD28- T lymphocytes by 4-1BB ligand. J Immunol 158:551-559.
27. Deeks SG, Wagner B, Anton PA et al (2002) A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 5:788-797.
28. Dembic Z, Haas W, Weiss S et al (1986) Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature 320:232-238.
29. Deschamps M, Mercier-Lethondal P, Certoux JM et al (2007) Deletions within the HSV-tk transgene in long-lasting circulating gene-modified T cells infused with a hematopoietic graft. Blood 110:3842-3852.
30. Dotti G, Savoldo B, Pule M et al (2005) Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood 105:4677-4684.
31. Eaton D, Gilham DE, O'Neill A et al (2002) Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions. Gene Ther 9:527-535.
32. Eshhar Z, Waks T, Gross G et al (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90:720-724.
33. Finney HM, Lawson AD, Bebbington CR et al (1998) Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 161:2791-2797.
34. Finney HM, Akbar AN, Lawson AD (2004) Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 172:104-113.
35. Friedmann-Morvinski D, Bendavid A, Waks T et al (2005) Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood 105:3087-3093.
36. Gade TP, Hassen W, Santos E et al (2005) Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res 65:9080-9088.
37. Garin MI, Garrett E, Tiberghien P et al (2001) Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood 97:122-129.
38. Gattenlohner S, Marx A, Markfort B et al (2006) Rhabdomyosarcoma lysis by T cells expressing a human autoantibody-based chimeric receptor targeting the fetal acetylcholine receptor. Cancer Res 66:24-28.
39. Gattinoni L, Klebanoff CA, Palmer DC et al (2005) Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115:1616-1626.
40. Gilham DE, O'Neil A, Hughes C et al (2002) Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zetabased chimeric immune receptors. J Immunother 25:139-151.
41. Gong MC, Latouche JB, Krause A et al (1999) Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1:123-127.
42. Gonzalez S, Naranjo A, Serrano LM et al (2004) Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma. J Gene Med 6:704-711.
43. Goverman J, Gomez SM, Segesman KD et al (1990) Chimeric immunoglobulin-T cell receptor proteins form functional receptors: implications for T cell receptor complex formation and activation. Cell 60:929-939.
44. Gross G, Waks T, Eshhar Z (1989) Expression of immunoglobulin-Tcell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 86:10024-10028.
45. Guest RD, Hawkins RE, Kirillova N et al (2005) The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother 28:203-211.
46. Habib-Agahi M, Phan TT, Searle PF (2007) Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells. Int Immunol 19:1383-1394.
47. Haynes NM, Snook MB, Trapani JA et al (2001) Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma. J Immunol 166:182-187.
48. Haynes NM, Trapani JA, Teng MW et al (2002a) Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100:3155-3163.
49. Haynes NM, Trapani JA, Teng MW et al (2002b) Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol 169:5780-5786.
50. Hekele A, Dall P, Moritz D et al (1996) Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:zeta-chimera. Int J Cancer 68:232-238.
51. Hinrichs CS, Spolski R, Paulos CM et al (2008) IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 111:5326-5333.
52. Hollyman D, Stefanski J, Przybylowski M et al (2009) Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother 32:169-180.
53. Hombach A, Heuser C, Sircar R et al (1997) T cell targeting of TAG72+ tumor cells by a chimeric receptorwith antibody-like specificity for a carbohydrate epitope. Gastroenterology 113:1163-1170.
54. Hombach A, Heuser C, Sircar R et al (1998) An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. Cancer Res 58:1116-1119.
55. Hombach AA, Schildgen V, Heuser C et al (2007) T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells. J Immunol 178:4650-4657.
56. Howard FD, Moingeon P, Moebius U et al (1992) The CD3 zeta cytoplasmic domain mediates CD2-induced T cell activation. J Exp Med 176:139-145.
57. Hurtado JC, Kim SH, Pollok KE et al (1995) Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28. J Immunol 155:3360-3367.
58. Huston JS, Levinson D, Mudgett-Hunter M et al (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 85:5879-5883.
59. Hwu P, Shafer GE, Treisman J et al (1993) Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med 178:361-366.
60. Hwu P, Yang JC, Cowherd R et al (1995) In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 55:3369-3373.
61. Imai C, Mihara K, Andreansky M et al (2004) Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18:676-684.
62. IntronaM, Barbui AM, Bambacioni F et al (2000) Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther 11:611-620.
63. Irving BA, Weiss A (1991) The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64:891-901.
64. Jakobsen MK, Restifo NP, Cohen PA et al (1995) Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line. J Immunother Emphas Tumor Immunol 17:222-228.
65. James SE, Greenberg PD, Jensen MC et al (2008) Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol 180:7028-7038.
66. Jensen M, Tan G, Forman S et al (1998) CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. Biol Blood Marrow Transplant 4:75-83.
67. Kahlon KS, Brown C, Cooper LJ et al (2004) Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 64:9160-9166.
68. Kershaw MH, Westwood JA, Zhu Z et al (2000) Generation of genemodified T cells reactive against the angiogenic kinase insert domain-containing receptor (KDR) found on tumor vasculature. Hum Gene Ther 11:2445-2452.
69. Kershaw MH, Westwood JA, Hwu P (2002) Dual-specific T cells combine proliferation and antitumor activity. Nat Biotechnol 20:1221-1227.
70. Kershaw MH, Jackson JT, Haynes NM et al (2004) Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer. J Immunol 173:2143-2150.
71. Kershaw MH, Westwood JA, Parker LL et al (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12:6106-6115.
72. Kieback E, Charo J, Sommermeyer D et al (2008) A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer. Proc Natl Acad Sci USA 105:623-628.
73. Klebanoff CA, Finkelstein SE, Surman DR et al (2004) IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA 101:1969-1974.
74. Kober J, Leitner J, Klauser C et al (2008) The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. Eur J Immunol 38:2678-2688.
75. Krause A, Guo HF, Latouche JB et al (1998) Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med 188:619-626.
76. Kuwana Y, Asakura Y, Utsunomiya N et al (1987) Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun 149:960-968.
77. Lamers CH, Sleijfer S, Vulto AG et al (2006) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24:e20-e22.
78. Lei XY, Xu YM, Wang T et al (2009) Knockdown of human bid gene expression enhances survival of CD8(+) T cells. Immunol Lett 122:30-36.
79. Letourneur F, Klausner RD (1991) T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. Proc Natl Acad Sci USA 88:8905-8909.
80. Li Y, Yee C (2008) IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood 111:229-235.
81. Li Q, Carr A, Ito F et al (2003) Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy. Cancer Res 63:2546-2552.
82. Li B, Wang H, Zhang D et al (2007a) Construction and characterization of a high-affinity humanized SM5-1 monoclonal antibody. Biochem Biophys Res Commun 357:951-956.
83. Li Q, Iuchi T, Jure-Kunkel MN et al (2007b) Adjuvant effect of anti- 4-1BB mAb administration in adoptive T cell therapy of cancer. Int J Biol Sci 3:455-462.
84. Lin J, Weiss A (2003) The tyrosine phosphatase CD148 is excluded from the immunologic synapse and down-regulates prolonged T cell signaling. J Cell Biol 162:673-682.
85. Liu K, Rosenberg SA (2001) Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J Immunol 167:6356-6365.
86. Lo AS, Taylor JR, Farzaneh F et al (2008) Harnessing the tumour derived cytokine, CSF-1, to co-stimulate T-cell growth and activation. Mol Immunol 45:1276-1287.
87. Loskog A, Giandomenico V, Rossig C et al (2006) Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 20:1819-1828.
88. Lou Y, Basha G, Seipp RP et al (2008) Combining the antigen processing components TAP and Tapasin elicits enhanced tumor-free survival. Clin Cancer Res 14:1494-1501.
89. Ma Q, Safar M, Holmes E et al (2004) Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. Prostate 61:12-25.
90. Maher J, Brentjens RJ, Gunset G et al (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 20:70-75.
91. Malek TR, Yu A, Vincek V et al (2002) CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17:167-178.
92. McGuinness RP, Ge Y, Patel SD et al (1999) Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. Hum Gene Ther 10:165-173.
93. Mendez MJ, Green LL, Corvalan JR et al (1997) Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet 15:146-156.
94. Mezzanzanica D, Canevari S, Mazzoni A et al (1998) Transfer of chimeric receptor gene made of variable regions of tumor specific antibody confers anticarbohydrate specificity on T cells. Cancer Gene Ther 5:401-407.
95. Milano F, Jorritsma T, Rygiel AM et al (2008) Expression pattern of immune suppressive cytokines and growth factors in oesophageal adenocarcinoma reveal a tumour immune escape-promoting microenvironment. Scand J Immunol 68:616-623.
96. Mitsuyasu RT, Anton PA, Deeks SG et al (2000) Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta genemodified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 96:785-793.
97. Moeller M, Haynes NM, Trapani JA et al (2004) A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells. Cancer Gene Ther 11:371-379.
98. Morgan RA, Dudley ME, Wunderlich JR et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126-129.
99. Morgan RA, Yang JC, Kitano M et al (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (in press).
100. Morgenroth A, Cartellieri M, Schmitz M et al (2007) Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate 67:1121-1131.
101. Mueller K, Schweier O, Pircher H (2008) Efficacy of IL-2-versus IL-15-stimulated CD8 T cells in adoptive immunotherapy. Eur J Immunol 38:2874-2885.
102. Muniappan A, Banapour B, Lebkowski J et al (2000) Ligandmediated cytolysis of tumor cells: use of heregulin-zeta chimeras to redirect cytotoxic T lymphocytes. Cancer Gene Ther 7:128-134.
103. Murata K, Nose M, Ndhlovu LC et al (2002) Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases. J Immunol 169:4628-4636.
104. Murphy A, Westwood JA, Brown LE et al (2007) Antitumor activity of dual-specific T cells and influenza virus. Cancer Gene Ther 14:499-508.
105. Niederman TM, Ghogawala Z, Carter BS et al (2002) Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci USA 99:7009-7014.
106. Nolan KF, Yun CO, Akamatsu Y et al (1999) Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin Cancer Res 5:3928-3941.
107. O'Connell J, O'Sullivan GC, Collins JK et al (1996) The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184:1075-1082.
108. Pameijer CR, Navanjo A, Meechoovet B et al (2007) Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor. Cancer Gene Ther 14:91-97.
109. Park JR, Digiusto DL, Slovak M et al (2007) Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 15:825-833.
110. Pegram HJ, Jackson JT, Smyth MJ et al (2008) Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo. J Immunol 181:3449-3455.
111. Pinthus JH, Waks T, Kaufman-Francis K et al (2003) Immuno-gene therapy of established prostate tumors using chimeric receptorredirected human lymphocytes. Cancer Res 63:2470-2476.
112. Pollok KE, Kim YJ, Zhou Z et al (1993) Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol 150:771-781.
113. Pollok KE, Kim SH, Kwon BS (1995) Regulation of 4-1BB expression by cell-cell interactions and the cytokines, interleukin-2 and interleukin-4. Eur J Immunol 25:488-494.
114. Pule MA, Straathof KC, Dotti G et al (2005) A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 12:933-941.
115. Pule MA, Savoldo B, Myers GD et al (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14:1264-1270.
116. Quintarelli C, Vera JF, Savoldo B et al (2007) Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 110:2793-2802.
117. Redmond WL, Gough MJ, Charbonneau B et al (2007) Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. J Immunol 179:7244-7253.
118. Ren-Heidenreich L, Mordini R, Hayman GT et al (2002) Comparison of the TCR zeta-chain with the FcR gamma-chain in chimeric TCR constructs for T cell activation and apoptosis. Cancer Immunol Immunother 51:417-423.
119. Richman SA, Aggen DH, Dossett ML et al (2009) Structural features of T cell receptor variable regions that enhance domain stability and enable expression as single-chain Valpha Vbeta fragments. Mol Immunol 46:902-916.
120. Robbins PF, Dudley ME, Wunderlich J et al (2004) Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 173:7125-7130.
121. Roberts MR, Qin L, Zhang D et al (1994) Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood 84:2878-2889.
122. Roessig C, Scherer SP, Baer A et al (2002) Targeting CD19 with genetically modified EBV-specific human T lymphocytes. Ann Hematol 81(Suppl 2):S42-S43.
123. Romeo C, Seed B (1991) Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 64:1037-1046.
124. Rosenberg SA, Dudley ME (2009) Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21:233-240.
125. Rossig C, Bollard CM, Nuchtern JG et al (2001) Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer 94:228-236.
126. Rossig C, Bollard CM, Nuchtern JG et al (2002) Epstein-Barr virusspecific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 99:2009-2016.
127. Savoldo B, Rooney CM, Di Stasi A et al (2007) Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 110:2620-2630.
128. Schluns KS, Williams K, Ma A et al (2002) Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. J Immunol 168:4827-4831.
129. Serafini M, Manganini M, Borleri G et al (2004) Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Hum Gene Ther 15:63-76.
130. Sheen AJ, Sherlock DJ, Irlam J et al (2003) T lymphocytes isolated from patients with advanced colorectal cancer are suitable for gene immunotherapy approaches. Br J Cancer 88:1119-1127.
131. Shibaguchi H, Luo NX, Kuroki M et al (2006) A fully human chimeric immune receptor for retargeting T-cells to CEA-expressing tumor cells. Anticancer Res 26:4067-4072.
132. Shuford WW, Klussman K, Tritchler DD et al (1997) 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 186:47-55.
133. Singh R, Paterson Y (2007) Immunoediting sculpts tumor epitopes during immunotherapy. Cancer Res 67:1887-1892.
134. Song E, Chen J, Ouyang N et al (2001) Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer. Br J Cancer 85:1047-1054.
135. Stancovski I, Schindler DG, Waks T et al (1993) Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol 151:6577-6582.
136. Stephan MT, Ponomarev V, Brentjens RJ et al (2007) T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med 13:1440-1449.
137. Straathof KC, Bollard CM, Popat U et al (2005a) Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105:1898-1904.
138. Straathof KC, Pule MA, Yotnda P et al (2005b) An inducible caspase 9 safety switch for T-cell therapy. Blood 105:4247-4254.
139. Teng MW, Kershaw MH, Moeller M et al (2004) Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes. Hum Gene Ther 15:699-708.
140. Tey SK, Dotti G, Rooney CM et al (2007) Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 13:913-924.
141. Thomis DC, Marktel S, Bonini C et al (2001) A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 97:1249-1257.
142. Tiberghien P, Ferrand C, Lioure B et al (2001) Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 97:63-72.
143. Till BG, Jensen MC, Wang J et al (2008) Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112:2261-2271.
144. Traversari C, Marktel S, Magnani Z et al (2007) The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood 109:4708-4715.
145. Turatti F, Figini M, Alberti P et al (2005) Highly efficient redirected anti-tumor activity of human lymphocytes transduced with a completely human chimeric immune receptor. J Gene Med 7:158-170.
146. van Meerten T, Claessen MJ, Hagenbeek A et al (2006) The CD20/alphaCD20 'suicide' system: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells. Gene Ther 13:789-797.
147. Vera J, Savoldo B, Vigouroux S et al (2006) T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 108:3890-3897.
148. Vera JF, Hoyos V, Savoldo B et al (2009) Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther 17:880-888.
149. Verhoeyen M, Milstein C, Winter G (1988) Reshaping human antibodies: grafting an antilysozyme activity. Science 239:1534-1536.
150. Walker RE, Bechtel CM, Natarajan V et al (2000) Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 96:467-474.
151. Wallace A, Kapoor V, Sun J et al (2008) Transforming growth factorbeta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res 14:3966-3974.
152. Wang J, Press OW, Lindgren CG et al (2004) Cellular immunotherapy for follicular lymphoma using genetically modified CD20- specific CD8+ cytotoxic T lymphocytes. Mol Ther 9:577-586.
153. Wang J, Jensen M, Lin Y et al (2007) Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther 18:712-725.
154. Wang X, Olszewska M, Capacio V et al (2008) Quantitative analysis of clinically relevant mutations occurring in lymphoid cells harboring gamma-retrovirus-encoded HSVTK suicide genes. Gene Ther 15:1454-1459.
155. Weijtens ME, Willemsen RA, van Krimpen BA et al (1998) Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules. Int J Cancer 77:181-187.
156. Westwood JA, Smyth MJ, Teng MW et al (2005) Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci USA 102:19051-19056.
157. Wilkie S, Picco G, Foster J et al (2008) Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol 180:4901-4909.
158. Willemsen RA, Ronteltap C, Chames P et al (2005) T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. J Immunol 174:7853-7858.
159. Yoon SH, Lee JM, Cho HI et al (2009) Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model. Cancer Gene Ther 16:489-497.
160. Yun CO, Nolan KF, Beecham EJ et al (2000) Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia 2:449-459.
161. Zhang T, He X, Tsang TC et al (2004) Transgenic TCR expression: comparison of single chain with full-length receptor constructs for T-cell function. Cancer Gene Ther 11:487-496.